- Home
- FAMI vs THAR Comparison
FAMI vs THAR Comparison
Compare FAMI & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- THAR
- Stock Information
- Founded
- FAMI 2015
- THAR 2017
- Country
- FAMI China
- THAR United States
- Employees
- FAMI N/A
- THAR N/A
- Industry
- FAMI Packaged Foods
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- THAR Health Care
- Exchange
- FAMI Nasdaq
- THAR Nasdaq
- Market Cap
- FAMI 3.4M
- THAR 2.8M
- IPO Year
- FAMI 2018
- THAR 2022
- Fundamental
- Price
- FAMI $0.28
- THAR $2.63
- Analyst Decision
- FAMI
- THAR
- Analyst Count
- FAMI 0
- THAR 0
- Target Price
- FAMI N/A
- THAR N/A
- AVG Volume (30 Days)
- FAMI 544.2K
- THAR 3.7M
- Earning Date
- FAMI 11-29-2024
- THAR 11-07-2024
- Dividend Yield
- FAMI N/A
- THAR N/A
- EPS Growth
- FAMI N/A
- THAR N/A
- EPS
- FAMI 0.13
- THAR N/A
- Revenue
- FAMI $86,261,500.00
- THAR N/A
- Revenue This Year
- FAMI N/A
- THAR N/A
- Revenue Next Year
- FAMI N/A
- THAR N/A
- P/E Ratio
- FAMI $2.28
- THAR N/A
- Revenue Growth
- FAMI N/A
- THAR N/A
- 52 Week Low
- FAMI $0.17
- THAR $1.84
- 52 Week High
- FAMI $2.35
- THAR $71.85
- Technical
- Relative Strength Index (RSI)
- FAMI 46.10
- THAR 55.35
- Support Level
- FAMI $0.28
- THAR $1.85
- Resistance Level
- FAMI $0.32
- THAR $2.33
- Average True Range (ATR)
- FAMI 0.03
- THAR 0.32
- MACD
- FAMI -0.00
- THAR 0.01
- Stochastic Oscillator
- FAMI 44.44
- THAR 62.65
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.